OptimizeRx (OPRX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Jun, 2026Executive summary
Proposal to amend the 2021 Equity Plan by adding an evergreen provision for automatic annual share increases through 2031, capped at 5% of outstanding shares each year.
The evergreen provision is intended to ensure sufficient equity for compensation, aligning employee and shareholder interests and supporting a shift to performance-based awards.
The amendment is designed to provide predictable dilution, maintain competitive compensation, and avoid frequent proxy filings for share pool increases.
The Board unanimously recommends voting in favor, citing strong governance and oversight mechanisms.
Voting matters and shareholder proposals
Shareholders are asked to approve the evergreen amendment to the 2021 Equity Plan (Proposal No. 4), which would allow for annual share pool increases for five years.
The Board believes the amendment is prudent, cost-effective, and consistent with historical authorization levels.
Approval would reduce administrative costs and preserve cash for business operations.
Board of directors and corporate governance
The Board retains discretion to reduce or eliminate annual share increases under the evergreen provision.
Stockholders maintain oversight through annual director elections and Say-on-Pay votes.
Material amendments to the equity plan require shareholder approval.
Latest events from OptimizeRx
- Directors elected, executive pay and equity plan increase approved, evergreen provision rejected.OPRX
AGM 202613 Jun 2026 - AI-powered point-of-care platform drives pharma ROI and growth through EHR integration and DSPs.OPRX
46th Annual William Blair Growth Stock Conference4 Jun 2026 - Q1 2026 revenue fell 10%, but profitability improved and guidance remains strong.OPRX
Q1 202613 May 2026 - Record 2025 growth, margin expansion, and $10M buyback set a strong but cautious 2026 outlook.OPRX
Q4 20256 May 2026 - Board recommends approval of all proxy proposals, including equity plan changes and auditor ratification.OPRX
Proxy filing30 Apr 2026 - Scalable platform drives pharma brand engagement and revenue growth in a large digital market.OPRX
Corporate presentation24 Mar 2026 - Q3 2025 saw 22% revenue growth, margin expansion, and raised guidance for 2025–2026.OPRX
Q3 20253 Feb 2026 - Q2 revenue up 36% to $18.8M, gross margin 62.2%, full-year guidance reaffirmed.OPRX
Q2 20242 Feb 2026 - Q3 revenue up 30% to $21.3M; 2024 guidance $88–92M, with strong margin and client growth.OPRX
Q3 202414 Jan 2026